Novo Nordisk's CagriSema Shows Promising Weight Loss Results with Mild Side Effects
TL;DR Summary
Novo Nordisk's obesity drug CagriSema, which combines Wegovy with a new medicine, showed promising weight loss results in studies, especially at lower doses, suggesting some patients respond well without needing the highest dose. The drug's safety profile is comparable to Wegovy, and the company plans to seek regulatory approval and conduct further studies, including head-to-head comparisons with competitors like Lilly's Zepbound.
- Novo Nordisk Obesity Shot Tied to Greater Weight Loss at Lower Doses Bloomberg
- Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects Reuters
- Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine Yahoo Finance
- Novo Nordisk’s amylin obesity drug keeps performing like Zepbound STAT
- Novo hunts for ‘maximum potential’ from obesity drug CagriSema Financial Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
91%
710 → 61 words
Want the full story? Read the original article
Read on Bloomberg